Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Acetylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.52 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | GMNN | O75496 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 3/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL3259109 | 0.98 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL7079427 | 0.98 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL13323920 | 0.98 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2639482 | 0.96 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL29376874 | 0.96 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2515409 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL4749513 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL28744378 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL20721036 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL27571008 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183228-B1 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES USEFUL AS CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS. | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-12 | — | — | EP | claimed |
| US-6797281-B1 | Esters of I-carnitine or alkanoyl I-carnitines | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-28 | — | — | US | claimed |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-23 | — | — | US | claimed |
| JP-2002541238-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1183228-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-03-06 | — | — | EP | claimed |
| WO-2000061543-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-19 | — | — | WO | claimed |
| WO-2017205550-A1 | IMMUNOGENIC COCHLEATES AND METHODS OF USE | MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-8598138-B2 | Amphiphilic nucleotide cochleate compositions and methods of using the same | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120232260-A1 | AMPHIPHILIC NUCLEOTIDE COCHLEATE COMPOSITIONS AND METHODS OF USING THE SAME | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20100178325-A1 | AMPHIPHILIC NUCLEOTIDE COCHLEATE COMPOSITIONS AND METHODS OF USING THE SAME | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7629003-B2 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-12-08 | — | — | US | disclosed |
| US-7585519-B2 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-08 | — | — | US | disclosed |
| WO-2008024389-A2 | AMPHIPHILIC NUCLEOTIDE COCHLEATE COMPOSITIONS AND METHODS OF USING THE SAME | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-5418253-A | Esters of L-carnitine and alkanoyl L-carnitines with glycolic acid or esters thereof and pharmaceutical compositions containing same for treating dermatoses | AVANTGARDE S.P.A. (IT) | 1995-05-23 | — | — | US | disclosed |
| EP-0631779-A1 | Use of esters of L-carnitine and acyl L-carnitine with hydroxyacids for producing pharmaceutical compositions for treating dermatoses | AVANTGARDE S.p.A. (IT) | 1995-01-04 | — | — | EP | disclosed |
| EP-0442850-B1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | SIGMA TAU IND FARMACEUTI (IT) | 1994-07-27 | — | — | EP | disclosed |
| EP-0596838-A2 | Esters of L-carnitine and alkanoyl L-carnitines with glycolic acid or esters thereof and pharmaceutical compositions containing same for treating dermatoses | AVANTGARDE S.p.A. (IT) | 1994-05-11 | — | — | EP | disclosed |
| US-5246967-A | USE OF ESTERS OF ACYL L-CARNITINES WITH GAMMA-HYDROXYBUTYRIC ACID FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOPATHIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-09-21 | — | — | US | disclosed |
| EP-0514357-A1 | Use of esters of acyl L-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-11-19 | — | — | EP | disclosed |
| EP-0442850-A1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178325-A1 | AMPHIPHILIC NUCLEOTIDE COCHLEATE COMPOSITIONS AND METHODS OF USING THE SAME | PHOSPHO1, NUDT1, SAMHD1 | CHRM2 3564/4885CHRM4 2200/4885CHRM1 3524/4885 |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CPT1B, SLC25A20, CRAT | CHRM2 2295/4885CHRM4 2806/4885CHRM1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.